Cigna

CI

Market cap $73.5B

Nonprofits can apply through May 15 for two-year grants supporting community–led solutions to reduce barriers to health LEARN MORE AND APPLY HERE MEMPHIS, Tenn., April 16, 2026 /PRNewswire/ -- Building on years of community investment and employee volunteerism across Tennessee, The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced the expansion of its Impact Fund to Memphis.

Customers rank myCigna highest for digital satisfaction as Cigna Healthcare continues to invest in AI-powered, personalized tools that make managing health care coverage  simpler and more reliable BLOOMFIELD, Conn., April 15, 2026 /PRNewswire/ -- Cigna Healthcare®, the health benefits division of The Cigna Group (NYSE: CI), ranked No.

US managed care insurers saw a notable bump to their stock prices this week following news of higher than anticipated Medicare Advantage rates for 2027. On April 6, the Centers for Medicare & Medicaid Services approved a net average rate increase of 2.48%, representing more than $13 billion in additional Medicare Advantage payments to plans for calendar year 2027.

Cigna Group remains a Buy, with catalysts for double-digit adjusted income per share growth resuming in 2027 and beyond. CI's pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks drive both topline and margin growth. Shares trade at an 8.5x forward P/E, a 29% discount to fair value, supporting a projected 17% annual total return through 2031.

Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BLOOMFIELD, Conn., April 2, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2026 financial results on Thursday, April 30, 2026, and will host a conference call the same day.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.

With grant funding, more than 20 nonprofit partners expanded access to stable housing and wraparound support services to support veteran communities in 10 states. Read the new Impact Report with outcomes in Arizona, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey, Pennsylvania, Tennessee and Texas.

CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.